Straits Times Index
3,144.76 -38.85 (-1.22%) S&P 500
5,051.41 -10.41 (-0.21%) Dow
37,798.97 +63.86 (+0.17%) Nasdaq
15,865.25 -19.77 (-0.12%) Bitcoin USD
63,715.32 +311.00 (+0.49%) CMC Crypto 200
885.54 0.00 (0.00%)
REGN Jan 2025 690.000 put
| Previous close | 11.30 |
| Open | 11.30 |
| Bid | 14.90 |
| Ask | 19.80 |
| Strike | 690.00 |
| Expiry date | 2025-01-17 |
| Day's range | 11.30 - 11.30 |
| Contract range | N/A |
| Volume | |
| Open interest | 125 |
ZacksWhy Regeneron (REGN) Could Beat Earnings Estimates Again
Regeneron (REGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
- Reuters
UPDATE 1-Regeneron to defend against DOJ complaint on drug-price manipulation
Regeneron Pharmaceuticals said on Monday it seeks to defend against U.S. Department of Justice's complaint that alleged the company misreported the average sales price of its macular degeneration drug Eylea. "Reimbursing credit card service fees to distributors is not a price concession and does not affect EYLEA's price," Regeneron said in a statement, adding that it considered the complaint to be "meritless". The DOJ last week, in a complaint filed in federal court in Boston, alleged the drugmaker failed for years to report how it paid hundreds of millions of dollars to subsidize Eylea purchases by reimbursing drug distributors for credit-card processing fees.
ReutersRegeneron to defend against DOJ complaint on drug-price manipulation
"Reimbursing credit card service fees to distributors is not a price concession and does not affect EYLEA's price," Regeneron said in a statement, adding that it considered the complaint to be "meritless". The DOJ last week, in a complaint filed in federal court in Boston, alleged the drugmaker failed for years to report how it paid hundreds of millions of dollars to subsidize Eylea purchases by reimbursing drug distributors for credit-card processing fees.
